Insight
Bilgen: MRD cancer detection shares same technical challenge as population screening
“If you can detect a microscopic level of DNA and be able to say that that is actually cancer, that is the same really technical problem as being able to detect those in healthy patients or, you know, general population.”
Insight
Bilgen: Interdisciplinary scientists accelerate R&D by an order of magnitude
“We have found that having that iterative cycle within one scientist actually accelerates the work that they do by an order of magnitude.”
Assertion Not checkable as stated
Bilgen: Direct early cancer detection requires raising over $1B pre-revenue
“If you wanted to solve early detection from the very beginning without having this step-by-step approach, you would have to raise more than a billion dollars, you know, without generating a single dollar of revenue.”
Assertion Supported
Bilgen: BillionToOne Processes Over 600,000 Tests Annually With ~20% Market Share
“We are processing more than 600,000 tests a year, and in terms of the overall market share, We are close to 20% market share there.”
Disclosure
Bilgen: Synthetic DNA removes PCR amplification noise from sequencing data
“So what we have done is to add a synthetic DNA into the patient sample that we get before any amplification happens. These synthetic DNA Allow us to know how much amplification happened at different genomic locations. You know, what are the errors that are bei…”
Insight
Bilgen: Chemistry experts rarely possess data science and bioinformatics skills
“People who understand chemistry Tend to be not the kind of data scientists and bioinformaticians that analyze the data.”
Assertion Supported
Bilgen: Fetal and tumor cell-free DNA are fundamentally identical to detect
“And, you know, we realized that, you know, fundamentally there is nothing different about, you know, cell-free fetal DNA and cell-free tumor DNA, and the same technology can be applied to both of them.”
What-if
Bilgen: Starting in oncology would have made initial commercialization far harder
“Because if we started, I think, on the oncology side, it would have been far more difficult to achieve that initial successful commercialization that gave us more resources to be able to build, you know, new tests and improve the existing tests.”
Disclosure
Bilgen: Small R&D teams own products and report directly to co-founders
“We actually have very small you know, research teams. It is essentially principal investigators, like a scientist who is interdisciplinary, who has a small team of, you know, two or three research associates, and they all directly report to David and me, and t…”
Disclosure
Bilgen: BillionToOne raised initial $300,000 in $10k checks over six months
“First 300,000 dollars that, you know, I've raised was, you know, really, really difficult. It took, you know, six months, and it was, you know, 10,000 dollars at a time”
Disclosure
Bilgen: BillionToOne had only one doctor ordering tests two months post-launch
“Launched in June, only person that is using the test, you know, two months later is this one Physician, and who is sending, like, maybe one or two tests per week.”
Prediction Open · timeframe Apr 2029
Bilgen: Current facility can scale to nearly two million tests annually
“We believe that we can expand into close to two million tests per year just using this facility. That would be, you know, around essentially every one in three babies that would be tested with our tests.”
Disclosure
Bilgen: Founders planned three-stage expansion from prenatal to early-stage cancer
“One year into the company, it is actually laid out that, you know, we would start at prenatal genetics, then go into late stage cancers, and then go into early stage cancers in this way.”
Assertion Supported
Bilgen: 20% of early-stage cancer surgery patients retain undetectable microscopic residue
“The problem is that in about 20% of these patients, actually, there is a microscopic residue remaining, and they cannot be detected by scans.”
